VIM and breast carcinoma: Our team has also recently reported that upregulation of α-tubulin (TUB), vimentin (VIM) and detyrosinated α-tubulin (GLU) in CTCs derived from breast cancer patients could be deployed as useful biomarkers to identify cancer cells with an aggressive phenotype.